Key facts
- It has raised $920K; the latest was Later Stage VC ($2.5M) in May 2025.
- Notable investors include Creative Destruction Lab, US National Science Foundation, Innovation Works, Richard King Mellon Foundation, Allegheny Health Network — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for MindTrace
- ·The full record, as it builds
Funding rounds
No funding rounds for MindTrace are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MindTrace
Developer of a functional brain mapping platform designed to improve neurosurgical planning and protect patient outcomes. The company offers software integrating advanced brain imaging, cloud-based computing, and the generation of pre-operative maps of sensory, cognitive, and motor functions, enabling neurosurgical teams to simulate surgical approaches, assess risk to critical brain areas, and reduce time and effort in analyzing complex brain data.
- Sector
- Healthcare
- HQ
- Pittsburgh, PA, United States
- Founded
- 2020
- Employees
- 6
- Website
- mindtrace.com/
- Ownership
- Privately Held (backing)
MindTrace doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MindTrace shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MindTrace in its N-PORT filings yet. We sweep new filings monthly.